BFC Planning, Inc.’s Ascendis Pharma A/S ASND Stock Holding History

BFC Planning, Inc.’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$221K	Buy	828 +30	+4%	+$7.01K	0.01%	897
2026 Q1	$183K	Hold	798	–	–	0.01%	907
2025 Q4	$170K	Buy	798 +26	+3%	+$5.37K	0.01%	930
2025 Q3	$153K	Buy	+772	New	+$144K	0.01%	763

Other funds holding ASND

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

BFC Planning, Inc.'s ASND Position: Q2 2026 in Review

BFC Planning, Inc. increased its Ascendis Pharma A/S (ASND) stake by 3.8% in Q2 2026, buying an estimated $7.01K and bringing the position to 828 shares worth $221K. The position accounts for 0.01% of the portfolio, ranked #897.

BFC Planning, Inc. first reported a position in ASND in Q3 2025 and has held it in 4 quarters since. 315 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

BFC Planning, Inc. held 828 shares of Ascendis Pharma A/S worth $221K as of Q2 2026.
BFC Planning, Inc. bought 30 Ascendis Pharma A/S shares in Q2 2026, an estimated $7.01K.
Ascendis Pharma A/S made up 0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #897 holding.
BFC Planning, Inc. first reported a position in Ascendis Pharma A/S in Q3 2025 and has held it in 4 quarters since.
315 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.